In two studies, the relevance of this tool has been evaluated in anti-β2GPI IgG positive patients subgrouped upon clinical presentation: thrombotic and/or obstetric APS, SARD, and asymptomatic aPL positivity. This evidence concerns the gene APOH and autoimmune polyendocrinopathy.